Effect of BioDMARDs on Diabetes risk in 6400+ Psoriasis pts IL-23i and IL-17Ai associated w/ -lower risks of diabetes -Diabetic nephropathy -Stage 3–5 CKD and reduced risk compared to TNFi treated and bionaive pts Adjustment on several variables, but not disease severity https://t.co/TDIHXJOC2T

• https://x.com/AurelieRheumo/status/1982514480211693706/photo/1
• https://x.com/AurelieRheumo/status/1982514480211693706/photo/1

Retrospective study by Dr. Goudot et al. - pts w/D2T PsA had dactylitis, fibromylagia & ischemic cardiomyopathy In multivariate analysis, FM & ischemic CM found to be RFs for D2T PsA ☝️Consider other dx if D2T PsA #ACR25 @RheumNow ABS0566 https://t.co/FOXv6LbysZ

• https://x.com/RHEUMarampa/status/1982501227062821053/photo/1

Icotrokinra, a first-in-class targeted oral peptide IL-23R inhibitor, cleared scalp (66%), genital (77%), and overall skin (57%) PsO vs placebo at Week 16. Basket trial design enabled targeted evaluation. Safety profile favorable. Abstract 0555 @RheumNow #ACR25

A systematic review by Dr. SRamiro et al evaluated efficacy of b/tsDMARDs on peripheral axSpA Majority on bDMARDs (TNFi, n=24; IL-17, n=13) Most of the SMDs were small --> b/tsDMARDs showed small to moderate effects on peripheral arthritis & enthesitis. #ACR25 @RheumNow Abs0588 https://t.co/yGXcqhZ1Uv

• https://x.com/RHEUMarampa/status/1982490153852833879/photo/1

Novelli et al. Upadacitinib in male vs female PsA. Data from SELECT-PsA studies. Appears equivalent in males and females, contrasting with TNFi/IL17i data. @RheumNow #ACR25 Abstr#557 https://t.co/fMKsbCkju0

• https://x.com/RichardPAConway/status/1982482604373787008/photo/1

Ogdie et al. Week 24 results of SOLSTICE study. Guselkumab in TNF-IR in PsA. Good efficacy on skin and joint disease. No difference seen in Q4 vs Q8 weekly doses. @RheumNow #ACR25 Abstr#563 https://t.co/ztK0O9iKb8

• https://x.com/RichardPAConway/status/1982481346682396779/photo/1

From the FOREMOST study factors predicting progression from oligo to polyarticular PsA: Female sex, enthesitis and dactylitis found to increase the risk of progression. Among patients in FOREMOST receiving PBO, prior csDMARD use was protective. Abstract#0576 @RheumNow #ACR25 https://t.co/CFMhAFgFBa

• https://x.com/synovialjoints/status/1982477323505906048/photo/1

Real-world T2T strategy from MONITOR-PsA cohort: 🎯 At 48 weeks - 33.6% (49/146) of pts achieved PASDAS 'moderate' response & 37% (54/146) achieved a 'good' response This was close to the T2T outcomes of the TICOPA trial Adapt a T2T approach in PsA tx #ACR25 @RheumNow Abs0572 https://t.co/FPiFIiO8Oe

• https://x.com/RHEUMarampa/status/1982477321555640449/photo/1
• https://x.com/RHEUMarampa/status/1982477321555640449/photo/1

Ribeiro et al. Case series of combination bDMARD/tsDMARD in PsA from Toronto. 24 patients, median just over a year follow-up. Appear effective, especially for objective skin and joint measures. No major safety concerns but short follow-up to date. @RheumNow #ACR25 Abstr#565 https://t.co/Zk3odT2EX2

• https://x.com/RichardPAConway/status/1982473041276981274/photo/1

Damen et al. 10-year follow-up of CRESPA study. Treatment withdrawl trial in early peripheral SpA. 38% in drug free remission. 82% in remission. @RheumNow #ACR25 Abstr#568 https://t.co/KOVW5pSbJg

• https://x.com/RichardPAConway/status/1982471531679670379/photo/1

This retrospective cohort analysis by Dr. Lihi Eder et al showed that among patients with PsA, those w/ high dse activity & high 3VAS scores were assoc w/⬆️ risk of atrial tachyarrythmias. Main message: PsA conveys ⬆️CV risk; inflamm control is key! #ACR25 @RheumNow Abs0522 https://t.co/7sRM7K4V1c

• https://x.com/RHEUMarampa/status/1982469770881683713/photo/1

High-resolution ultrasound detected subclinical enthesitis in 44% of psoriasis patients without arthritis and 12% had PD positivity. Supports a preclinical PsA phase and use of MSUS to detect entheseal inflammation in both symptomatic and asymptomatic PsO patients for timely

Basic Sci Year in Review: Dr. Anne Davidson discusses the potential pathologic link bet tryptophan, indole, I3S & IL-17 pathways. I3S induces epidermal thickening in mice and correlated with dse activity in patients with #psoriasis #ACR25 @RheumNow https://t.co/WNNbBBESQ3

• https://x.com/RHEUMarampa/status/1982439692046864485/photo/1